Johnson & Johnson unit minimized risks of drug - report

	Tweet

Janssen Pharmaceutica Products, a unit of Johnson & Johnson, notified doctors that it minimized the risks of a popular drug for schizophrenia in promotional materials, according to the Associated Press.

Janssen sent a two-page letter to health care providers this week to clarify the risks of the drug, the report said, citing Janssen spokeswoman Carol Goodrich.

Goodrich did not immediately return a phone message left by Reuters.

Last year the Food and Drug Administration told several makers of antipsychotic drugs to update their product labels.

The agency determined that Janssen’s promotional material minimized the risk of strokes, diabetes, and other potentially fatal complications, according to the AP. The agency also said that Janssen had made misleading claims that the medication was safer than similar drugs. 

RELATED STORIES:
Autism Genes Discovered; Help Shape Connections Among Brain Cells   Diagnosis, abortion of Down’s babies rising in UK   Early parenting plays key role in infants’ physiological response to stress   Research at Marshall University may lead to new treatments for Parkinson’s disease and other neurological disorders   Iowa’s DHS Says It Will Guard Mental Health Records   Flu exposure in womb may raise schizophrenia risk   Do women really talk more than men?   Mental Health of Prisoners   Testosterone shut-off doesn’t affect men’s mood   Prognostic factors for tobacco consumption reduction after relapse   Stress may increase risk for Alzheimer’s disease   Babytalk has roots in evolution, expert says

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]